Oseltamivir Treatment and Prophylaxis Guidelines

Introduction to Oseltamivir Indications

The American Academy of Pediatrics (AAP), Centers for Disease Control and Prevention (CDC), Infectious Diseases Society of America (IDSA), and Pediatric Infectious Diseases Society (PIDS) strongly recommend oseltamivir for severe, complicated, or progressive influenza regardless of time since symptom onset or vaccination status 2, 3, 4

Hospitalized patients with confirmed or suspected influenza, regardless of symptom duration, should receive oseltamivir treatment 3, 4
Immunocompromised patients, including those on long-term corticosteroid therapy, should receive oseltamivir treatment 1
Children under 2 years of age, who are at increased risk of complications, should receive oseltamivir treatment 2, 4
Pregnant women should receive oseltamivir treatment 1
Elderly patients should receive oseltamivir treatment 1
Patients with compromised respiratory function requiring mechanical ventilation or baseline oxygen should receive oseltamivir treatment 3

Treatment after 48 hours of symptom onset should be offered to patients with moderate-to-severe or progressive disease, as it has demonstrated benefit 2, 4
Earlier treatment provides better clinical responses, but delayed treatment still offers benefit in severe cases 2, 4
In hospitalized adults with severe influenza, treatment initiated ≤5 days after symptom onset was associated with reduced mortality (adjusted OR 0.50) 2

Oseltamivir reduces illness duration by 17.6 hours in children (29.9 hours when excluding children with asthma) 1
Oseltamivir is associated with a 50% reduction in pneumonia risk 1
Oseltamivir is associated with a 34% reduction in otitis media risk in children 1, 2
Oseltamivir reduces the risk of death within 15 days of hospitalization (OR 0.21) 1
Oseltamivir has a 58.5% to 89% efficacy in household contacts when started within 48 hours of exposure 1

Oseltamivir prophylactic dosing is once daily at the same weight-based amounts used for treatment 1
Treatment should not be delayed while waiting for laboratory confirmation in high-risk patients 4, 5
No benefit from double-dose therapy compared to standard dosing 2
Vomiting occurs in approximately 5% of treated patients (15% in children vs 9% with placebo) 2, 4
Oseltamivir may be less effective for influenza B than influenza A 5